Galectin Therapeutics Q1 net loss $9.9M ($0.17/shr); cash runway through May 2023

GALECTIN THERAPEUTICS INC

2022-Q1 EPS reported -$0.17

Net loss of $9.9M for Q1 2022 vs $6.3M in Q1 2021; R&D spend rose to $8.1M (up from $4.9M) on NAVIGATE trial costs.
Cash and equivalents $31.6M; company expects to fund operations through at least May 16, 2023.
Expects to require additional $40-45M to reach planned interim analysis of NAVIGATE trial in mid-2024.
Phase 2b/3 NAVIGATE trial enrollment for NASH cirrhosis on track to finish Phase 2b portion around Q3 2022.
Company preparing IND to study belapectin in combination with Keytruda for recurrent head and neck cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported the three months ended March 31, 2022 results: net income net loss applicable to common stockholders of $9.9 million, EPS ($0.17) per share.

Period: the three months ended March 31, 2022
Net income: net loss applicable to common stockholders of $9.9 million
EPS: ($0.17) per share
Result: reported results

Exact text from the filing

For the three months ended March 31, 2022, the Company reported a net loss applicable to common stockholders of $9.9 million, or ($0.17) per share

View on SEC.gov

Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-22-019249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.